Tumor Escape

"Tumor Escape" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The ability of tumors to evade destruction by the IMMUNE SYSTEM. Theories concerning possible mechanisms by which this takes place involve both cellular immunity (IMMUNITY, CELLULAR) and humoral immunity (ANTIBODY FORMATION), and also costimulatory pathways related to CD28 antigens (CD28 ANTIGENS) and CD80 antigens (B7-1 ANTIGEN).

Descriptor ID	D019139
MeSH Number(s)	G12.900
Concept/Terms	Tumor Escape Tumor Escape Tumor Immune Evasion Evasion, Tumor Immune Evasions, Tumor Immune Immune Evasions, Tumor Tumor Immune Evasions Immune Evasion, Tumor Immune Escape, Tumor Tumor Immune Escape

Below are MeSH descriptors whose meaning is more general than "Tumor Escape".

Biological Sciences [G]
Immune System Phenomena [G12]
Tumor Escape [G12.900]

Below are MeSH descriptors whose meaning is more specific than "Tumor Escape".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Tumor Escape" by people in this website by year, and whether "Tumor Escape" was a major or minor topic of these publications.

Bar chart showing 14 publications over 10 distinct years, with a maximum of 2 publications in 2011 and 2014 and 2019 and 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2005	0	1	1
2008	1	0	1
2010	0	1	1
2011	2	0	2
2012	1	0	1
2014	2	0	2
2018	0	1	1
2019	1	1	2
2020	0	1	1
2021	0	2	2

Below are the most recent publications written about "Tumor Escape" by people in Profiles.

Brochez L, Kruse V, Schadendorf D, Muller AJ, Prendergast GC. Editorial: Targeting Indoleamine 2,3-dioxygenases and Tryptophan Dioxygenase for Cancer Immunotherapy. Front Immunol. 2021; 12:789473.

View in: PubMed
Sinha G, Ferrer AI, Ayer S, El-Far MH, Pamarthi SH, Naaldijk Y, Barak P, Sandiford OA, Bibber BM, Yehia G, Greco SJ, Jiang JG, Bryan M, Kumar R, Ponzio NM, Etchegaray JP, Rameshwar P. Specific N-cadherin-dependent pathways drive human breast cancer dormancy in bone marrow. Life Sci Alliance. 2021 07; 4(7).

View in: PubMed
La Fleur L, Botling J, He F, Pelicano C, Zhou C, He C, Palano G, Mezheyeuski A, Micke P, Ravetch JV, Karlsson MCI, Sarhan D. Targeting MARCO and IL37R on Immunosuppressive Macrophages in Lung Cancer Blocks Regulatory T Cells and Supports Cytotoxic Lymphocyte Function. Cancer Res. 2021 02 15; 81(4):956-967.

View in: PubMed
Nagpal P, Descalzi-Montoya DB, Lodhi N. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes. Cancer Rep (Hoboken). 2021 04; 4(2):e1311.

View in: PubMed
Inaguma S, Lasota J, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okon K, Biernat W, Schrump DS, Hassan R, Kasai K, Miettinen M, Ikeda H. CD70 expression correlates with a worse prognosis in malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness. J Pathol. 2020 02; 250(2):205-216.

View in: PubMed
Keenan BP, Fong L, Kelley RK. Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. J Immunother Cancer. 2019 10 18; 7(1):267.

View in: PubMed
Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond. Semin Immunopathol. 2019 01; 41(1):41-48.

View in: PubMed
Stephen TL, Rutkowski MR, Allegrezza MJ, Perales-Puchalt A, Tesone AJ, Svoronos N, Nguyen JM, Sarmin F, Borowsky ME, Tchou J, Conejo-Garcia JR. Transforming growth factor ?-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. Immunity. 2014 Sep 18; 41(3):427-439.

View in: PubMed
Prendergast GC, Smith C, Thomas S, Mandik-Nayak L, Laury-Kleintop L, Metz R, Muller AJ. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother. 2014 Jul; 63(7):721-35.

View in: PubMed
Harris DT. Alterations in target cell membrane phospholipids alter T cell but not NK cell killing. Immunobiology. 2013 Jan; 218(1):21-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement